Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet's stock experienced a 15% decline in November 2025 following its Q3 2025 earnings release due to sales softness and reduced revenue growth guidance. In February 2026, the company reported Q4 and full-year 2025 results, exceeding revenue and EPS forecasts, leading to a 4.3% stock increase and a new $1.5 billion stock repurchase authorization. Analyst ratings have shifted, with upgrades from Wall Street Zen and TD Cowen, but the consensus remains a "Hold" with an average price target of $106.20. Over the last 12 months, the stock's price has decreased by 15.48%.

Demand for Zimmer Biomet's products is driven by orthopedic procedures, influenced by aging demographics and elective surgeries. While specific seasonal patterns are not detailed, a surge in demand was experienced in Q4 2025. The company anticipates that an aging global population will continue to fuel strong long-term demand for joint replacements.

Zimmer Biomet Holdings, Inc. is a global medical technology company focused on musculoskeletal healthcare, designing, manufacturing, and marketing orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, spine, CMFT products, dental implants, and surgical equipment. The company also offers integrated digital and robotic technologies like the ROSA Robot and ZBEdge Platform.

Zimmer Biomet has a global presence segmented across the Americas, EMEA, and Asia Pacific. The Americas include the U.S. and other markets in North, Central, and South America. The EMEA segment includes key European countries such as France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment covers significant markets like Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia.

Zimmer Biomet's brand reputation faced scrutiny after an investigation by Hagens Berman in November 2025, reiterated in February 2026, following disclosures of emerging market failures and inconsistent execution. In April 2026, the appointment of Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer could positively impact the company's scientific standing. The company has also been recognized on Forbes lists such as "America's Best Companies" and "Global 2000: United States".

Zimmer Biomet has a significant institutional ownership base, including major shareholders like Dodge & Cox, The Vanguard Group, and BlackRock, Inc. Institutional investors collectively hold a substantial portion of the company's shares, with some reports indicating over 100% institutional ownership. Individual insider ownership is also present, though to a lesser extent.